Craft

Bone Biologics

Stock Price

$1.4

2024-10-29

Market Capitalization

$3.6 M

2024-10-29

Revenue

$1.1 B

FY, 2020

Bone Biologics Summary

Company Summary

Overview
Bone Biologics is a medical device company focused on bone regeneration in spinal fusion. It develops a bone graft substitute product,NELL-1/DBX, an osteostimulative recombinant protein that provides target-specific control over bone regeneration. The company also provides a platform technology to the spine, trauma, and osteoporosis treatment markets.
Type
Public
Status
Active
Founded
2004
HQ
Burlington, MA, US | view all locations
Website
https://www.bonebiologics.com
Cybersecurity rating
Sectors

Key People

  • Jeff Frelick

    Jeff Frelick, Chief Executive Officer President

  • Deina Walsh

    Deina Walsh, Chief Financial Officer

  • Don R. Hankey

    Don R. Hankey, Chairman

    • Bruce Stroever

      Bruce Stroever, Director

      LocationsView all

      1 location detected

      • Burlington, MA HQ

        United States

        2 Burlington Woods Dr #100

      Bone Biologics Financials

      Summary Financials

      Net income (Q1, 2026)
      ($766.0K)
      Cash (Q1, 2026)
      $4.5M
      EBIT (Q1, 2026)
      ($805.1K)

      Footer menu